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Abstract
Objectives: Eosinophilic fasciitis (EF) was described in 1974 by Shulman as a rare fibrosing connec-
tive tissue disease of unknown etiology. An undetermined trigger is thought to lead to the degran-
ulation of eosinophils that interact with fibroblasts and express fibrogenic cytokines including the 
transforming factor of tumor growth a and b and interleukins 1 and 6. The purpose of this study was 
to summarize seven cases of EF in a central hospital.
Material and methods: This was a retrospective and descriptive study of a population with EF of 
a central hospital. All patients diagnosed with EF in a hospital unit were admitted to the study be-
tween January 1, 2005, and April 30, 2018.
Results: A total of seven patients diagnosed with EF were analyzed. The median age of the popula-
tion at the time of diagnosis was 56 years, and 57% of the patients were women. All patients had 
elevated peripheral eosinophilia and sedimentation rate, and only one patient had hypergamma-
globulinemia. All patients had edema and cutaneous thickening of the limbs, 57% had constitu-
tional symptoms, and 57% had inflammatory arthritis with joint contracture. Prednisolone (PDN) 
therapy was initiated in all patients, and only in two was the association of PDN with methotrexate 
(MTX) initially performed. In one patient triple therapy of PDN, MTX, and cyclosporine was required. 
At the time of this publication, only one patient maintains active disease, and tocilizumab has been 
initiated.
Conclusions: Recent studies show a more favorable response from the combination of PDN and 
MTX than from PDN alone. Considering the rarity of the disease, more long-term studies are needed 
regarding the etiopathogenetics, progression, recurrence of EF, and new effective therapies.
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Introduction
In 1974 Shulman [1] described a rare scleroderma-like 
syndrome designated as eosinophilic fasciitis (EF). Eo-
sinophilic fasciitis is rare disease characterized by sub-
acute onset of erythema, edema, and induration of the 
skin and soft tissues of the limbs and trunk [2]. These 
manifestations are replaced by fascial fibrosis, leading to 
a cobblestone appearance or peau d’orange, as well as 
the “groove sign,” a linear depression along the course 
of veins, accentuated by limb elevation, due to inward 
tethering of the skin. Concurrent plaque morphea can be 
present in 29–41% of cases. Extracutaneous involvement 
includes muscle pain and weakness [3], neuropathies such 
as carpal tunnel syndrome (23%) [4], articular symptoms 
like joint contractures (50–56%) [5], and arthritis (40%) [6], 
with a high impact of morbidity related to EF. Visceral in-
volvement is rare, but some cases have been reported as 
pericarditis [7], pleural effusions [8], and renal involvement.
Laboratory evaluation often reveals peripheral eosin-
ophilia (58–85%) [9], hypergammaglobulinemia (36–46%) 
[7] monoclonal gammopathy (16%) [8], and an elevated 
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erythrocyte sedimentation rate (ESR), although it is not 
mandatory for the diagnosis.
The incidence of EF is uncertain. It occurs most com-
monly in middle-aged individuals, with peak incidence 
between 40 and 50 years of age. 
The pathogenesis of EF is not well understood. Eo-
sinophils degranulate and induce tissue damage, which 
results in fibrosis via accumulation of extracellular ma-
trix. Various studies have indicated that eosinophils in-
teract with fibroblasts and express fibrogenic cytokines 
including tumor growth factor (TGF) α, TGF-β, interleukin 
(IL) 1, and IL-6 [10].
There are some possible triggering factors or factors 
associated with EF, such as infections [11], initiation of 
hemodialysis [12], radiotherapy, graft-versus-host dis-
ease, hematological disorders, as well as autoimmune 
diseases [13] (primary biliary cirrhosis, systemic lupus 
erythematosus, Sjögren’s syndrome). Other reasons for 
EF are also taken into account, such us: exposure to cer-
tain medications [14] (ramipril, phenytoin, subcutaneous 
heparin, statins), strenuous exercise, or trauma. However, 
most cases are considered as idiopathic. Rarely, EF can be 
associated with solid or hematological neoplasms [15]. 
Hematological abnormalities associated with EF include 
the following: multiple myeloma, lymphoma, myelodys-
plastic syndromes, myeloproliferative disorders, acquired 
amegakaryocytic thrombocytopenia, aplastic anemia, 
and paroxysmal nocturnal hemoglobinuria.
The diagnosis of EF is based on clinical features com-
plemented by laboratory findings; however, universally 
accepted international diagnostic criteria are lacking. 
A full-thickness skin biopsy including the fascia usually 
confirms the diagnosis by demonstrating characteristic 
lymphocytic and eosinophilic infiltrate with thickened 
collagen bundles in the fascia. Magnetic resonance im-
aging (MRI) should be performed when the biopsy is 
non-diagnostic or cannot be obtained. Findings on MRI 
show an increased T2 signal in subcutaneous and deep 
fascia and enhancement of these structures on fat-sup-
pressed T1 images after gadolinium administration. 
If MRI cannot be performed, 18-F-fluorodeoxyglucose 
positron emission tomography/computed tomography 
(FDG-PT/CT) [16] or ultrasound should be performed [17].
There are a variety of other disorders that should be 
considered in the differential diagnosis of EF. Systemic 
sclerosis (SSc) is the main differential diagnosis of EF. 
Sometimes EF can be misdiagnosed and there are some 
features that can help clinicians distinguish these two 
entities. In EF there is no skin tightening of distal digits, 
nailfold capillary changes, digital ulcers, or Raynaud’s 
phenomenon. Histopathology in EF universally involves 
fascia and involvement of the dermis, subcutaneous fat, 
and muscle may occur, whereas in SSc only dermis and 
subcutaneous fat are involved [18]. 
Localized scleroderma includes morphea and linear 
scleroderma. These entities have a slowly progressive 
course and are not associated with significant eosinophilia.
In scleroderma-like disorders we can find skin thick-
ening and decreased pliability. Scleromyxedema can oc-
cur alone or in association with malignancies. Scleroder-
ma is associated with diabetes, plasma cell disorder, and 
monoclonal gammopathy. In the skin biopsy of sclero-
derma there is no evidence of inflammation.
Early treatment of patients with EF showed better 
outcomes in some studies, but these findings were not 
statically significant [19].
Currently, systemic corticosteroids (SCS) are the corner-
stone of treatment. In those patients who develop a ste-
roid-resistant disease the introduction of an immunosup-
pressive drug is essential. The most common agent used 
is methotrexate (MTX), especially in patients with mor-
phea-like skin lesions. Other treatment options include hy-
droxychloroquine, azathioprine, cyclophosphamide, cyclo-
sporine, or an anti-TNF agent (etanercept). There are some 
recent studies showing the efficacy of a therapy targeting 
IL-6 cytokine, tocilizumab (TCZ), in EF refractory to steroids 
and other immunosuppressive drugs [20].
Material and methods
This was an observational, retrospective, and de-
scriptive study based on the population of Clinical Im-
munology Unit (CIU) in a single central hospital between 
January 1, 2005, and April 30, 2018. 
Population 
All adult patients diagnosed with EF followed in CIU. 
EF diagnosis was based on suggestive clinical, laborato-
ry findings and with a biopsy-proven fascia involvement.
Data collection
We collected demographic and clinical data regis-
tered on the clinical software (SClinico®) of all patients. 
Age and gender were used as demographic variables. 
Clinical variables included evolution time of disease, 
anatomic localization of disease, and personal and fa-
miliar medical history. Other considered variables relat-
ed to extracutaneous involvement were constitutional 
symptoms, history of edema, inflammatory arthritis, 
morning stiffness, hyperpigmented lesions, Raynaud 
syndrome, dysphagia or gastroesophageal reflux dis-
ease, and carpal tunnel syndrome.
The laboratory variables considered were peripheral 
eosinophilia, gammaglobulinemia, complement, antinu-
clear antibodies, and erythrocyte sedimentation rate.
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Series of EF are rarely published. The purpose of this 
study was to summarize seven cases, showing the clin-
ical findings, laboratory results, histological characteris-
tics, and immunosuppressive treatment used. 
Results
Study sample
A total of seven patients were followed in CIU be-
tween January 2005 and April 2018. Mean age at diagno-
sis was 56 ±21.1 years, and four patients were women. 
At the time of the study, patients had an average of 11 
(1–41) years of disease progression.
Table I shows patients’ characteristics such as ana-
tomic localization of EF, and signs and symptoms and 
laboratory findings.
Regarding the anatomic localization, arms, forearms, 
and thighs were the most affected. Only one patient had 
familiar and personal history of autoimmune disease. 
The immunological laboratory results such as antinucle-
ar antibodies (ANA) and antineutrophil cytoplasmic anti-
bodies (ANCA) were negative. Thyroid function (TSH, ft4, 
and ft3), thyroid peroxidase antibody (TPO), thyroglob-
ulin antibody (TGAb), and thyroid stimulating hormone 
receptor antibody (TSHRAb) were negative.
In laboratory findings, all patients had peripheral eo-
sinophilia and elevated ESR, and only one patient had 
hypergammaglobulinemia. None of the patients pre-
sented abnormalities in complement component levels. 
All patients had history of edema and skin induration. 
Constitutional symptoms and inflammatory arthritis 
with joint contracture were present in 57% of patients. 
Raynaud phenomenon and visceral involvement were 
not present in the described patients.
Nailfold capillaroscopy was performed in three pa-
tients, two of them were normal picture of naifoild cap-
illaires and one showed nonspecific alterations. A full 
thickness incisional skin biopsy was performed in all pa-
Table I. Patients’ characteristics
Feature Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Diagnosis age (years) 5 60 28 56 36 56 61
Current age (years) 19 67 69 63 42 58 62
Gender Female Female Female Male Male Male Female
Anatomic localization
Face – – + – – – –
Trunk – + – – – – +
Arms – – + + + + +
Forearm – – – + + + +
Hands + – + – – – –
Abdomen – + – + – – +
Thighs – – + + + – +
Ankle + – – – – – –
Familiar history autoimmune 
disease
+ – – – – – –
Personal history autoimmune 
disease
Vitiligo – – – – – –
Laboratory findings
Eosinophilia 10.4% 8.3% 9.2% 10% 9.1% 9.2% 10.3%
Gammaglobulinemia – – + – – – –
Antinuclear antibodies 1/160 1/80 1/80 1/60 1/80 1/160 1/80
Erythrocyte sedimentation rate 
(mm/h)
80 60 65 60 54 65 68
Signs and symptoms
Constitutional symptoms + + – – + – +
Inflammatory arthritis + + – – + – +
Morning stiffness – + – – + – +
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tients, and histopathological assessment revealed infil-
trated lymphocytes, plasma cells, histiocytes, and eosin-
ophils. MRI was performed in one patient and showed 
thickening and global hypersignal of the forearm.
Immunosuppressive treatment
Table II shows the immunosuppressive treatment 
used in the treatment of analyzed patients. Prednisolone 
(PDN) was initiated in all patients with a 0.5–1 mg/kg/
day initial dose. In this study, in only two patients was 
the combination of PDN with MTX initially performed 
(patients 4 and 7). The median time between disease 
onset and MTX initiation was three months, and the 
maximum dose was 20 mg/week. One patient required 
triple therapy of PDN, MTX, and cyclosporine (initial dose 
200 mg). Disease recurrence was observed only in one 
patient. Only one patient maintains active disease, and 
due the exuberant extension of fasciitis, subcutaneous 
tocilizumab 162 mg/week was initiated eight months 
after the disease onset. Six patients (86%) achieved dis-
ease remission after a median time of 12 months (range, 
3–24 months). No patient underwent psoralen and ul-
traviolet A therapy.
Discussion
Shulman’s disease is rare, and high clinical suspicion 
is needed for the diagnosis, which can be difficult be-
cause of the differential diagnoses that should be con-
sidered.
Typical clinical manifestations include edema and 
skin thickening, with orange peel skin texture, and 
groove sign, with more common involvement in the ex-
tremities, neck, and trunk. Complaints of myalgias and 
muscle weakness are common. Inflammatory arthritis is 
only present in a minority of patients. In these patients, 
sclerodactyly and Raynaud’s syndrome are absent, as 
well as visceral involvement, and hence they are com-
patible with this study [21].
Rarely, some conditions can accompany the disease 
like compartment syndrome [22], esophageal dysmotil-
ity [23], reactive hepatitis [24], contractures in the joints 
due to edema [25], and peripheral polyneuropathy [26]. 
Contractures in the joints were found in 57% of patients, 
which can be very disabling and drastically reduce the 
quality of life.
Frequent analytical findings include peripheral eo-
sinophilia, which may be transient, increased ESR, and 
polyclonal hypergammaglobulinemia. The laboratory ab-
normalities can be transitory and are not mandatory for 
the diagnosis. In this study, peripheral eosinophilia was 
present in all patients.
In most cases, the diagnosis is confirmed by skin bi-
opsy (thickening of the fascia with accumulation of lym-
phocytes and macrophages with or without eosinophilic 
infiltrate) [18], and in this study the result of the biopsy 
was consistent with the suspected disease. Magnetic 
resonance imaging may be performed in atypical cases 
or if the biopsy does not confirm the diagnosis.
The differential diagnoses include neoplasia, infec-
tions, systemic sclerosis and other scleroderma subsets 
such as morphea, and epidemic fasciitis syndromes 
caused by toxic agents such as myalgia-eosinophilia 
syndrome and toxic oil syndrome [27]. Neoplasia should 
be suspected when corticosteroid therapy is refractory. 
In our study, none of the patients had an underlying dis-
ease diagnosed.
Table II. Immunosuppressive treatment
Therapeutics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
PDN initial dose (mg) 20 40 30 20 60 80 60
PDN maximum dose (mg) 20 40 30 20 60 80 60
Time for introduction  
of another (months)
14 3 1 0 1 – 0
MTX initial dose (mg)/week 17,5 5 10 10 5 – 7.5
MTX maximal dose (mg)/week 25 15 20 20 17.5 – 20
Time for introduction  
of another (months)
– – – 3 – – 8
Current therapeutics MTX 12.5 
mg/week
PDN 5 mg 
+ MTX 15 
mg/week
MTX 17.5 
mg/week
CCP 100 
mg/daily + 
PDN 5 mg/
daily 
MTX 7.5 
mg/week
PDN 5 mg PDN 20 mg/
daily + MTX 20 
mg/week + TCZ 
162 mg/week
Active disease – – – – – – +
Disease recurrence – – + – – – –
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The standard treatment is systemic corticosteroid 
therapy [28]. Recent studies show a more favorable re-
sponse of the combination of PDN and MTX than of PDN 
alone [29].
Currently there are new therapies that can improve 
the outcome of these patients, and it is fundamental 
to establish effective therapy as early as possible, to 
obtain a better prognosis. The introduction of a thera-
py targeting IL-6 cytokine in the case of EF refractory to 
steroids and other immunosuppressive drugs has been 
described [30]. In this study, TCZ at 162 mg for three 
months showed softening of the skin with a significant 
reduction of skin hardness.
Limitations of our study include its retrospective de-
sign and small study size.
Conclusions
Eosinophilic fasciitis is a rare disease that may pres-
ent a variable spectrum of clinical manifestations.
The variability of the age, presentation form, and 
laboratory changes make the EF challenging from the 
point of view of the possible differential diagnoses, as 
well as the therapeutic management.
Considering the rarity of the disease, more long-term 
studies are needed regarding the etiopathogenesis, pro-
gression, recurrence of EF, and new effective therapies.
The authors declare no conflict of interest.
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